Wall Street is positive on Crispr Therapeutics AG (CRSP). On average, analysts give CRSP a Strong Buy rating. The average price target is $137.8, which means analysts expect the stock to climb by 153.17% over the next twelve months. That average ranking earns CRSP an Analyst Rating of 51, which is better than 51% of stocks based on data compiled by InvestorsObserver.
Where Does Wall Street Think Crispr Therapeutics AG (CRSP) Stock Will Go?
Wall Street analysts are rating CRSP a Strong Buy today. Find out what this means to you and get the rest of the rankings on CRSP!